The cost-effectiveness of adding an ultrasound corticosteroid and local anaesthetic injection to advice and education for hip osteoarthritis
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVES: Evidence for the comparative cost-effectiveness of intra-articular corticosteroid injection in people with hip osteoarthritis (OA) remains unclear. This study investigated the cost-effectiveness of best current treatment (BCT) comprising advice and education plus a single ultrasound-guided intra-articular hip injection (USGI) of 40 mg triamcinolone acetonide and 4 ml 1% lidocaine hydrochloride (BCT+US-T) versus BCT alone.
METHODS: A trial-based cost-utility analysis of BCT+US-T compared with BCT was undertaken over 6 months. Patient-level cost data were obtained, and effectiveness was measured in terms of quality-adjusted life years (QALYs), allowing the calculation of cost per QALY gained from a United Kingdom (UK) National Health Service (NHS) perspective.
RESULTS: BCT+US-T was associated with lower mean NHS costs (BCT+US-T minus BCT: £-161.6, 95% CI: £-583.95 to £54.18) and small but significantly higher mean QALYs than BCT alone over 6 months (BCT+US-T minus BCT: 0.0487, 95% CI: 0.0091, 0.0886). In the base case, BCT+US-T was the most cost-effective and dominated BCT alone. Differences in total costs were driven by number of visits to NHS consultants, private physiotherapists, and chiropractors, and hip surgery, which were more common with BCT alone than BCT+US-T.
CONCLUSION: Intra-articular corticosteroid injection plus BCT (BCT+US-T) for patients with hip OA results in lower costs and better outcomes, and is highly cost-effective, compared with BCT alone.
TRIAL REGISTRATION: EudraCT: 2014-003412-37 (August 8, 2015) and registered with Current Controlled Trials: ISRCTN 50550256 (July 28, 2015).
TRIAL PROTOCOL: Full details of the trial protocol can be found in the Supplementary Appendix, available with the full text of this article at https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-018-2153-0#citeas.
DOI: doi.org/10.1186/s12891-018-2153-0.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - (2023) vom: 12. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kigozi, Jesse [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Corticosteroid injection |
|---|
| Anmerkungen: |
Date Revised 12.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/rheumatology/kead659 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365759368 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365759368 | ||
| 003 | DE-627 | ||
| 005 | 20231229123604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead659 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365759368 | ||
| 035 | |a (NLM)38085178 | ||
| 035 | |a (PII)kead659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kigozi, Jesse |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The cost-effectiveness of adding an ultrasound corticosteroid and local anaesthetic injection to advice and education for hip osteoarthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a OBJECTIVES: Evidence for the comparative cost-effectiveness of intra-articular corticosteroid injection in people with hip osteoarthritis (OA) remains unclear. This study investigated the cost-effectiveness of best current treatment (BCT) comprising advice and education plus a single ultrasound-guided intra-articular hip injection (USGI) of 40 mg triamcinolone acetonide and 4 ml 1% lidocaine hydrochloride (BCT+US-T) versus BCT alone | ||
| 520 | |a METHODS: A trial-based cost-utility analysis of BCT+US-T compared with BCT was undertaken over 6 months. Patient-level cost data were obtained, and effectiveness was measured in terms of quality-adjusted life years (QALYs), allowing the calculation of cost per QALY gained from a United Kingdom (UK) National Health Service (NHS) perspective | ||
| 520 | |a RESULTS: BCT+US-T was associated with lower mean NHS costs (BCT+US-T minus BCT: £-161.6, 95% CI: £-583.95 to £54.18) and small but significantly higher mean QALYs than BCT alone over 6 months (BCT+US-T minus BCT: 0.0487, 95% CI: 0.0091, 0.0886). In the base case, BCT+US-T was the most cost-effective and dominated BCT alone. Differences in total costs were driven by number of visits to NHS consultants, private physiotherapists, and chiropractors, and hip surgery, which were more common with BCT alone than BCT+US-T | ||
| 520 | |a CONCLUSION: Intra-articular corticosteroid injection plus BCT (BCT+US-T) for patients with hip OA results in lower costs and better outcomes, and is highly cost-effective, compared with BCT alone | ||
| 520 | |a TRIAL REGISTRATION: EudraCT: 2014-003412-37 (August 8, 2015) and registered with Current Controlled Trials: ISRCTN 50550256 (July 28, 2015) | ||
| 520 | |a TRIAL PROTOCOL: Full details of the trial protocol can be found in the Supplementary Appendix, available with the full text of this article at https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-018-2153-0#citeas | ||
| 520 | |a DOI: doi.org/10.1186/s12891-018-2153-0 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a corticosteroid injection | |
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a cost-utility | |
| 650 | 4 | |a economic evaluation | |
| 650 | 4 | |a hip osteoarthritis | |
| 700 | 1 | |a Oppong, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Paskins, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Bromley, Kieran |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Martyn |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Hennings, Susie |e verfasserin |4 aut | |
| 700 | 1 | |a Cherrington, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Holden, Melanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Stevenson, Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Ajit |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Peat, George |e verfasserin |4 aut | |
| 700 | 1 | |a Jinks, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Nadine E |e verfasserin |4 aut | |
| 700 | 1 | |a Mallen, Christian D |e verfasserin |4 aut | |
| 700 | 1 | |a Roddy, Edward |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g (2023) vom: 12. Dez. |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead659 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 12 | ||